Tag: Mind Cure - Psilocybin Alpha

New Resource: Psychedelics Drug Development Tracker

MINDCURE Shares Update on Strong Financial Position, Near Term Revenue Drivers and Timeline for iSTRYM’s Market Launch, Delivering Mental Wealth

MINDCURE Shares Update on Strong Financial Position, Near Term Revenue Drivers and Timeline for iSTRYM’s Market Launch, Delivering Mental Wealth

Post published:April 29, 2021
Post category:Press Release

MINDCURE Announces Partnership with SOMA Breath Inc. to License its Breathwork Program and Develop Custom Breathwork for Psychedelic-Assisted Psychotherapies within iSTRYM

MINDCURE Announces Partnership with SOMA Breath Inc. to License its Breathwork Program and Develop Custom Breathwork for Psychedelic-Assisted Psychotherapies within iSTRYM

Post published:April 27, 2021
Post category:Press Release

MINDCURE Partners its iSTRYM Technology with LUCID to Discover and Create Proprietary Music Experiences for Use During Psychedelic-Assisted Therapy Sessions

MINDCURE Partners its iSTRYM Technology with LUCID to Discover and Create Proprietary Music Experiences for Use During Psychedelic-Assisted Therapy Sessions

Post published:April 21, 2021
Post category:Press Release

MINDCURE Announces Partnership with Speak Ai to Enhance iSTRYM, the Company’s Psychedelic Digital Therapeutics Technology Platform

MINDCURE Announces Partnership with Speak Ai to Enhance iSTRYM, the Company’s Psychedelic Digital Therapeutics Technology Platform

Post published:April 13, 2021
Post category:Press Release

MINDCURE Announces Additional Equity Investment in ATMA, The First Government Approved Psychedelic Journey Centers In Canada; MCUR President and CEO, Kelsey Ramsden Named to ATMA Board of Directors

MINDCURE Announces Additional Equity Investment in ATMA, The First Government Approved Psychedelic Journey Centers In Canada; MCUR President and CEO, Kelsey Ramsden Named to ATMA Board of Directors

Post published:April 8, 2021
Post category:Press Release

MINDCURE Files Provisional Patent Application For iSTRYM, its Proprietary AI Digital Therapeutics (DTx) SaaS Platform, Designed To Enhance Effectiveness Of Psychedelic-Assisted Therapies For Practitioners And Patients

MINDCURE Files Provisional Patent Application For iSTRYM, its Proprietary AI Digital Therapeutics (DTx) SaaS Platform, Designed To Enhance Effectiveness Of Psychedelic-Assisted Therapies For Practitioners And Patients

Post published:March 31, 2021
Post category:Press Release

Ty Tashiro joins MINDCURE as the Senior Translational and Psychometric Architect for iSTRYM’s AI-Driven Psychedelic Digital Therapeutic Technology

Ty Tashiro joins MINDCURE as the Senior Translational and Psychometric Architect for iSTRYM’s AI-Driven Psychedelic Digital Therapeutic Technology

Post published:March 19, 2021
Post category:Press Release

MINDCURE Names Tarik Lebbadi as Chief Operating Officer

MINDCURE Names Tarik Lebbadi as Chief Operating Officer

Post published:March 15, 2021
Post category:Press Release

MINDCURE Receives Unconditional Ethics Approval for its Psychedelic Integration Protocol Research Study

MINDCURE Receives Unconditional Ethics Approval for its Psychedelic Integration Protocol Research Study

Post published:March 9, 2021
Post category:Press Release

MINDCURE Discovers Potential Opportunity for Ibogaine-Assisted Psychotherapy to Treat Neuropathic Pain and Traumatic Brain Injury

MINDCURE Discovers Potential Opportunity for Ibogaine-Assisted Psychotherapy to Treat Neuropathic Pain and Traumatic Brain Injury

Post published:March 4, 2021
Post category:Press Release

End of content

No more pages to load

Psilocybin Alpha

The definitive resource for investors in the emergent psychedelic medicine sector. Cut through the shroom stock noise with exclusive news, interviews, data and private financing opportunities.

Quick Links

Newsletter

Industry insights and interviews delivered to your inbox. No spam, just valuable information.